Adeno-associated virus-mediated delivery of glial cell line-derived neurotrophic factor protects motor neuron-like cells from apoptosis.
Motor neuron disorders including amyotrophic lateral sclerosis may benefit from the induction of neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF) that are known to be trophic and protective for motor neurons. However, the application of such factors is limited by an inability to successfully target their expression in the nervous system. In this study we investigate the potential of using adeno-associated virus (AAV) as a vector for gene delivery into motor neuron-like cells. In initial experiments on the motor neuron cell line NSC-19 using a recombinant AAV vector expressing the reporter gene beta-galactosidase (AAV-LacZ), we successfully demonstrate the utility of AAV for gene transfer. In addition, a recombinant AAV vector expressing GDNF was shown to express and secrete high levels of the neurotrophic factor into the surrounding media of NSC-19 infected cells. Finally, the AAV-GDNF vector is demonstrated to act in a neuroprotective fashion. Withdrawal of trophic support from NSC-19 cells through serum deprivation results in a subsequent increase in the number of cells entering apoptosis. However, the percentage of apoptotic cells are significantly reduced in cells infected with the AAV-GDNF vector, as compared to AAV-LacZ or uninfected controls. This work demonstrates the potential of using AAV as a vector in motor neuron-like cells and should prove important in devising future gene therapy strategies for the treatment of in vivo motor neuron disorders.
Keir
S D
SD
University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland, UK. sk34x@clinmed.gla.ac.uk
Xiao
X
X
Li
J
J
Kennedy
P G
PG
D000818:Animals; D017209:Apoptosis; D002460:Cell Line; D017077:Culture Media, Conditioned; D016895:Culture Media, Serum-Free; D000229:Dependovirus / Q000235:genetics*; D017930:Genes, Reporter; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006801:Humans; D006822:Hybrid Cells; D007668:Kidney; D051379:Mice; D016472:Motor Neuron Disease / Q000628:therapy; D009046:Motor Neurons / Q000378:metabolism / Q000473:pathology*; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000502:physiology; D009447:Neuroblastoma / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000502:physiology; D013116:Spinal Cord / Q000166:cytology / Q000196:embryology; D014162:Transfection; D001616:beta-Galactosidase / Q000235:genetics
D017077:Culture Media, Conditioned; D016895:Culture Media, Serum-Free; C495039:GDNF protein, human; C495040:Gdnf protein, mouse; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D011993:Recombinant Fusion Proteins; D001616:beta-Galactosidase